Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Translated title of the contribution: Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
  • Trial Investigators DREAM
  • , G.R. Dagenais
  • , H.P.F. Koppeschaar
  • , J. Poque
  • , S. Yusuf

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionEffects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Original languageUndefined/Unknown
Pages (from-to)1007-1014
Number of pages8
JournalDiabetes Care
Volume31
Issue number5
Publication statusPublished - 2008

Cite this